Avacta Group acquires Coris Bioconcept to expand diagnostics business
LONDON, UK: Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announced today that it has acquired Coris Bioconcept SRL (“Coris”) for an upfront cash consideration of £7.4 million (on a debt-free/cash-free…